Skip to main content
. 2021 Nov 11;14(11):e243745. doi: 10.1136/bcr-2021-243745

Figure 3.

Figure 3

Evolution of extramedullary relapse of blastic-chronic myeloid leukaemia activity by positron emission tomography (PET)-CT. (A) Tumour observed on PET-CT on July 2018 after treatment with cytarabine and daunorubicin (7+3). (B) Tumour observed after first cycle of azacytidine 75 mg/m2 for 7 days plus venetoclax ramped up to 400 mg/day. (C) Cessation of tumour activity after treatment with blinatumomab plus gemtuzumab plus high doses of cytarabine.